BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geller A, Yan J. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy. Front Immunol 2019;10:1074. [PMID: 31164885 DOI: 10.3389/fimmu.2019.01074] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Bharti R, Dey G, Lin F, Lathia J, Reizes O. CD55 in cancer: Complementing functions in a non-canonical manner. Cancer Letters 2022;551:215935. [DOI: 10.1016/j.canlet.2022.215935] [Reference Citation Analysis]
2 Emtenani S, Holtsche MM, Stahlkopf R, Seiler DL, Burn T, Liu H, Parker M, Yilmaz K, Dikmen HO, Lang MH, Sadik CD, Karsten CM, van Beek N, Ludwig RJ, Köhl J, Schmidt E. Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.942493] [Reference Citation Analysis]
3 Yuan M, Liu L, Wang C, Zhang Y, Zhang J. The Complement System: A Potential Therapeutic Target in Liver Cancer. Life (Basel) 2022;12:1532. [PMID: 36294966 DOI: 10.3390/life12101532] [Reference Citation Analysis]
4 Senent Y, Tavira B, Pio R, Ajona D. The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells. Cancer Lett 2022;549:215900. [PMID: 36087681 DOI: 10.1016/j.canlet.2022.215900] [Reference Citation Analysis]
5 Arora G, Lynn GE, Tang X, Rosen CE, Hoornstra D, Sajid A, Hovius JW, Palm NW, Ring AM, Fikrig E. CD55 Facilitates Immune Evasion by Borrelia crocidurae, an Agent of Relapsing Fever. mBio 2022;:e0116122. [PMID: 36036625 DOI: 10.1128/mbio.01161-22] [Reference Citation Analysis]
6 Chopra D, Arens RA, Amornpairoj W, Lowes MA, Tomic-canic M, Strbo N, Lev-tov H, Pastar I. Innate immunity and microbial dysbiosis in hidradenitis suppurativa – vicious cycle of chronic inflammation. Front Immunol 2022;13:960488. [DOI: 10.3389/fimmu.2022.960488] [Reference Citation Analysis]
7 Xu H, Wang H, Xing T, Wang X. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes. Front Immunol 2022;13:851622. [DOI: 10.3389/fimmu.2022.851622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ayala C, Sathe A, Bai X, Grimes SM, Shen J, Poultsides GA, Lee B, Ji HP. Distinct cell states define the developmental trajectories of mucinous appendiceal neoplasms towards pseudomyxoma metastases.. [DOI: 10.1101/2022.05.26.493618] [Reference Citation Analysis]
9 Liu Y, Xu L, Hao C, Wu J, Jia X, Ding X, Lin C, Zhu H, Zhang Y. Identification and Validation of Novel Immune-Related Alternative Splicing Signatures as a Prognostic Model for Colon Cancer. Front Oncol 2022;12:866289. [DOI: 10.3389/fonc.2022.866289] [Reference Citation Analysis]
10 Son SW, Cho E, Cho H, Woo SR, Lee H, Oh SJ, Kim S, Kim J, Chung EJ, Chung J, Kim MG, Song K, Kim TW. NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-12692-6] [Reference Citation Analysis]
11 Luo S, Su T, Zhou X, Hu WX, Hu J. Chromosome 1 instability in multiple myeloma: Aberrant gene expression, pathogenesis, and potential therapeutic target. FASEB J 2022;36:e22341. [PMID: 35579877 DOI: 10.1096/fj.202200354] [Reference Citation Analysis]
12 Kolka CM, Webster J, Lepletier A, Winterford C, Brown I, Richards RS, Zelek WM, Cao Y, Khamis R, Shanmugasundaram KB, Wuethrich A, Trau M, Brosda S, Barbour A, Shah AK, Eslick GD, Clemons NJ, Morgan BP, Hill MM. C5b-9 Membrane Attack Complex Formation and Extracellular Vesicle Shedding in Barrett's Esophagus and Esophageal Adenocarcinoma. Front Immunol 2022;13:842023. [PMID: 35345676 DOI: 10.3389/fimmu.2022.842023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lima T, Barros AS, Trindade F, Ferreira R, Leite-moreira A, Barros-silva D, Jerónimo C, Araújo L, Henrique R, Vitorino R, Fardilha M. Application of Proteogenomics to Urine Analysis towards the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study. Cancers 2022;14:2001. [DOI: 10.3390/cancers14082001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer 2022. [PMID: 35393541 DOI: 10.1038/s41568-022-00466-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
15 Saad AA. Targeting cancer-associated glycans as a therapeutic strategy in leukemia. All Life 2022;15:378-433. [DOI: 10.1080/26895293.2022.2049901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 van der Koog L, Gandek TB, Nagelkerke A. Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization. Adv Healthc Mater 2022;11:e2100639. [PMID: 34165909 DOI: 10.1002/adhm.202100639] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 28.0] [Reference Citation Analysis]
17 Yan Y, Liu XY, Lu A, Wang XY, Jiang LX, Wang JC. Non-viral vectors for RNA delivery. J Control Release 2022;342:241-79. [PMID: 35016918 DOI: 10.1016/j.jconrel.2022.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
18 Lorizate M, Terrones O, Nieto-Garai JA, Rojo-Bartolomé I, Ciceri D, Morana O, Olazar-Intxausti J, Arboleya A, Martin A, Szynkiewicz M, Calleja-Felipe M, Bernardino de la Serna J, Contreras FX. Super-Resolution Microscopy Using a Bioorthogonal-Based Cholesterol Probe Provides Unprecedented Capabilities for Imaging Nanoscale Lipid Heterogeneity in Living Cells. Small Methods 2021;5:e2100430. [PMID: 34928061 DOI: 10.1002/smtd.202100430] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
19 Szadai L, Velasquez E, Szeitz B, Almeida NP, Domont G, Betancourt LH, Gil J, Marko-Varga M, Oskolas H, Jánosi ÁJ, Boyano-Adánez MDC, Kemény L, Baldetorp B, Malm J, Horvatovich P, Szász AM, Németh IB, Marko-Varga G. Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out. Cancers (Basel) 2021;13:6105. [PMID: 34885218 DOI: 10.3390/cancers13236105] [Reference Citation Analysis]
20 Netti GS, Franzin R, Stasi A, Spadaccino F, Dello Strologo A, Infante B, Gesualdo L, Castellano G, Ranieri E, Stallone G. Role of Complement in Regulating Inflammation Processes in Renal and Prostate Cancers. Cells 2021;10:2426. [PMID: 34572075 DOI: 10.3390/cells10092426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
21 Wang C, Jie J, Li D, Liu Y, Gao J, Song L. Clinical value of CD97 and CD55 levels in the differential diagnosis of tuberculous and malignant pleural effusions. Medicine (Baltimore) 2021;100:e26771. [PMID: 34397724 DOI: 10.1097/MD.0000000000026771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Senent Y, Ajona D, González-Martín A, Pio R, Tavira B. The Complement System in Ovarian Cancer: An Underexplored Old Path. Cancers (Basel) 2021;13:3806. [PMID: 34359708 DOI: 10.3390/cancers13153806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kra G, Nemes-Navon N, Daddam JR, Livshits L, Jacoby S, Levin Y, Zachut M, Moallem U. Proteomic analysis of peripheral blood mononuclear cells and inflammatory status in postpartum dairy cows supplemented with different sources of omega-3 fatty acids. J Proteomics 2021;246:104313. [PMID: 34216809 DOI: 10.1016/j.jprot.2021.104313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Khan A, Das BC, Abiha U, Sisodiya S, Chikara A, Nazir SU, Das AM, Rodrigues AG, Passari AK, Tanwar P, Hussain S, Rashid S, Rashid S. Insights into the role of complement regulatory proteins in HPV mediated cervical carcinogenesis. Semin Cancer Biol 2021:S1044-579X(21)00161-9. [PMID: 34087416 DOI: 10.1016/j.semcancer.2021.05.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Liszewski MK, Atkinson JP. Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections. Curr Opin Immunol 2021;72:126-34. [PMID: 34004375 DOI: 10.1016/j.coi.2021.04.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
26 Jang KO, Lee YW, Kim H, Chung DK. Complement Inactivation Strategy of Staphylococcus aureus Using Decay-Accelerating Factor and the Response of Infected HaCaT Cells. Int J Mol Sci 2021;22:4015. [PMID: 33924622 DOI: 10.3390/ijms22084015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Jiang YQ, Wang ZX, Zhong M, Shen LJ, Han X, Zou X, Liu XY, Deng YN, Yang Y, Chen GH, Deng W, Huang JH. Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data. Oncoimmunology 2021;10:1908010. [PMID: 33868792 DOI: 10.1080/2162402X.2021.1908010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
28 Zhu H, Yu X, Zhang S, Shu K. Targeting the Complement Pathway in Malignant Glioma Microenvironments. Front Cell Dev Biol 2021;9:657472. [PMID: 33869223 DOI: 10.3389/fcell.2021.657472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
29 O'Brien RM, Cannon A, Reynolds JV, Lysaght J, Lynam-Lennon N. Complement in Tumourigenesis and the Response to Cancer Therapy. Cancers (Basel) 2021;13:1209. [PMID: 33802004 DOI: 10.3390/cancers13061209] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
30 Bao D, Zhang C, Li L, Wang H, Li Q, Ni L, Lin Y, Huang R, Yang Z, Zhang Y, Hu Y. Integrative Analysis of Complement System to Prognosis and Immune Infiltrating in Colon Cancer and Gastric Cancer. Front Oncol 2020;10:553297. [PMID: 33614473 DOI: 10.3389/fonc.2020.553297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
31 Li L, Cong B, Yu X, Deng S, Liu M, Wang Y, Wang W, Gao M, Xu Y. The expression of membrane-bound complement regulatory proteins CD46, CD55 and CD59 in oral lichen planus. Arch Oral Biol 2021;124:105064. [PMID: 33529836 DOI: 10.1016/j.archoralbio.2021.105064] [Reference Citation Analysis]
32 Akhir FNM, Noor MHM, Leong KWK, Nabizadeh JA, Manthey HD, Sonderegger SE, Fung JNT, McGirr CE, Shiels IA, Mills PC, Woodruff TM, Rolfe BE. An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer. Antibodies (Basel) 2021;10:2. [PMID: 33430104 DOI: 10.3390/antib10010002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
33 Mahmoud HH, Nasef NM, Eldewi DM, Galal RKF. Role of Complement Regulatory Proteins (CD55, CD59, and CD35) on Red Blood Cells of <i>β</i>-Thalassaemia Patients. OJBD 2021;11:89-104. [DOI: 10.4236/ojbd.2021.114010] [Reference Citation Analysis]
34 van Tetering G, Evers M, Chan C, Stip M, Leusen J. Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents. Antibodies (Basel) 2020;9:E70. [PMID: 33333967 DOI: 10.3390/antib9040070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
35 Kim BJ, Mastellos DC, Li Y, Dunaief JL, Lambris JD. Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Prog Retin Eye Res 2021;83:100936. [PMID: 33321207 DOI: 10.1016/j.preteyeres.2020.100936] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
36 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
37 Elvington M, Liszewski MK, Atkinson JP. CD46 and Oncologic Interactions: Friendly Fire against Cancer. Antibodies (Basel) 2020;9:E59. [PMID: 33147799 DOI: 10.3390/antib9040059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
38 Elieh Ali Komi D, Shafaghat F, Kovanen PT, Meri S. Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy 2020;75:2818-28. [PMID: 32446274 DOI: 10.1111/all.14413] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
39 Golay J, Taylor RP. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies (Basel) 2020;9:E58. [PMID: 33126570 DOI: 10.3390/antib9040058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
40 Kavvadas E. Autoantibodies specific for C1q, C3b, β2-glycoprotein 1 and annexins may amplify complement activity and reduce apoptosis-mediated immune suppression. Med Hypotheses 2020;144:110286. [PMID: 33254588 DOI: 10.1016/j.mehy.2020.110286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Hensen LCM, Hoeben RC, Bots STF. Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy. Int J Mol Sci 2020;21:E6828. [PMID: 32957644 DOI: 10.3390/ijms21186828] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
42 Taylor RP, Lindorfer MA. How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2. Antibodies (Basel) 2020;9:E45. [PMID: 32899722 DOI: 10.3390/antib9030045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Zhu C, Song Z, Wang A, Srinivasan S, Yang G, Greco R, Theilhaber J, Shehu E, Wu L, Yang ZY, Passe-Coutrin W, Fournier A, Tai YT, Anderson KC, Wiederschain D, Bahjat K, Adrián FJ, Chiron M. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Front Immunol 2020;11:1771. [PMID: 32922390 DOI: 10.3389/fimmu.2020.01771] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 16.5] [Reference Citation Analysis]
44 Olkhov-Mitsel E, Hodgson A, Liu SK, Vesprini D, Bayani J, Bartlett J, Xu B, Downes MR. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study. J Clin Pathol 2021;74:53-7. [PMID: 32471889 DOI: 10.1136/jclinpath-2020-206631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Ma WJ, Shi YH, Chen J. Ayu (Plecoglossus altivelis) CD46 isoforms protect the cells from autologous complement attack. Fish Shellfish Immunol 2020;102:267-75. [PMID: 32360277 DOI: 10.1016/j.fsi.2020.04.057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Yoo SM, Lee MS. Kaposi's Sarcoma-Associated Herpesvirus and Host Interaction by the Complement System. Pathogens 2020;9:E260. [PMID: 32260199 DOI: 10.3390/pathogens9040260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Makatsariya AD, Elalamy I, Vorobev AV, Bakhtina AS, Meng M, Bitsadze VO, Khizroeva JK. Thrombotic microangiopathy in cancer patients. Annals RAMS 2019;74:323-332. [DOI: 10.15690/vramn1204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Tu L, Guan R, Yang H, Zhou Y, Hong W, Ma L, Zhao G, Yu M. Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival. Int J Cancer 2020;147:423-39. [DOI: 10.1002/ijc.32785] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 22.0] [Reference Citation Analysis]